Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Parthika Patel

M. Pharm (Pharmaceutics)

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Home

Parthika Patel

Articles By : Parthika Patel

CDSCO Cancels Import Licence of Mediderma Salipeel Products

CDSCO Cancels Cosmetic Import Registration of Indian Agent for Proteos Biotech

Parthika Patel11 Aug 2025 3:45 PM IST

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has cancelled the Cosmetic Registration Certificate No. RC/COS-003595, held by NKG...

CDSCO Panel Accepts Glenmark's Apremilast Trial Report, Seeks 2-Year PSUR Data

Parthika Patel10 Aug 2025 1:00 PM IST

New Delhi: Glenmark Pharmaceuticals Limited has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs...

Intas Pharma Gets Expert Panel Nod For PMS Data On Tofacitinib Ointment In Atopic Dermatitis

Parthika Patel9 Aug 2025 11:30 AM IST

New Delhi: Intas Pharma has received approval from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO)...

Abbott to Conduct BE Study for Carbimazole 15 mg, Trial Waiver Granted In India

Parthika Patel8 Aug 2025 2:34 PM IST

New Delhi: Abbott Healthcare Pvt. Ltd has received the green signal from the Subject Expert Committee (SEC) under the Central Drugs Standard Control...

Dr Reddy's Gets CDSCO Panel Approval To Begin Phase III Trial of Tapinarof Cream

Parthika Patel7 Aug 2025 11:41 PM IST

New Delhi: Dr. Reddy's Laboratories Limited has received approval from the Subject Expert Committee (SEC) under CDSCO to conduct a Phase III clinical...

No Waiver for Faricimab: CDSCO Panel Asks Roche to Conduct Phase III Trial in India

Parthika Patel6 Aug 2025 3:34 PM IST

New Delhi: Roche Products (India) Pvt Ltd has been directed by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation...

Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial Proposal

Parthika Patel3 Aug 2025 9:30 AM IST

New Delhi: Novartis Healthcare Private Limited has been directed by the Subject Expert Committee (SEC) functional under the Central Drugs Standard...

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray

Parthika Patel2 Aug 2025 4:51 PM IST

New Delhi: Biodeal Pharmaceuticals Limited has been directed by the National Pharmaceutical Pricing Authority (NPPA) to submit documents supporting...

CDSCO Panel Accepts Phase I Trial Data for Intas' Denosumab Biosimilar

Parthika Patel2 Aug 2025 4:40 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Analgesic and Rheumatology division of the Central Drugs Standard Control Organisation (CDSCO)...

Submit BE Raw Data, Interaction Study on Dapagliflozin-Rosuvastatin FDC: Expert Panel Tells Pure and Cure

CDSCO Panel Clears PURE & CURE's Sickle Cell Trial With Conditions On Sample Size, Sites

Parthika Patel1 Aug 2025 5:09 PM IST

New Delhi: PURE & CURE Healthcare Pvt. Ltd. has received a recommendation from the Subject Expert Committee (SEC) under the Central Drugs Standard...

CDSCO Panel Withholds Nod for Syngene's Pegfilgrastim Trial, Seeks Additional Data

Parthika Patel31 July 2025 2:01 PM IST

New Delhi: The Subject Expert Committee under the Central Drugs Standard Control Organisation (CDSCO) has directed Syngene International Limited to...

Zydus Told To Conduct Phase III Trial in India for Lurbinectedin Injection, BE Study Waived

Parthika Patel31 July 2025 1:49 PM IST

New Delhi: Zydus Lifesciences Limited has been directed to conduct a Phase III clinical trial in the Indian population for its proposed oncology drug...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok